News
Innovative Cellular Therapeutics (ICT) Announces Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting 1000 667 Innovative Cellular Therapeutics

Innovative Cellular Therapeutics (ICT) Announces Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

ROCKVILLE, MARYLAND, May 26th, 2022 (GLOBE NEWSWIRE) – Innovative Cellular Therapeutics, Inc. (ICT), a clinical-stage biotechnology company developing a comprehensive portfolio of chimeric antigen receptor (CAR) T cell therapies for solid tumors, today announced the acceptance of an abstract for poster presentation at the upcoming 2022 ASCO Annual meeting in Chicago, IL from June 3-7,…

Innovative Cellular Therapeutics (ICT) to Present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting 1000 1500 Innovative Cellular Therapeutics

Innovative Cellular Therapeutics (ICT) to Present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting

ROCKVILLE, MARYLAND, May 17th, 2022 (GLOBE NEWSWIRE) – Innovative Cellular Therapeutics, Inc. (ICT), a clinical-stage biotechnology company developing a comprehensive portfolio of chimeric antigen receptor (CAR) T cell therapies for solid tumors, today announced the Company will present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual meeting in Washington DC. May…

Innovative Cellular Therapeutics (ICT) Announces Data Presentation at the American Association for Cancer Research (AACR) Annual Meeting   1000 667 Innovative Cellular Therapeutics

Innovative Cellular Therapeutics (ICT) Announces Data Presentation at the American Association for Cancer Research (AACR) Annual Meeting  

Clinical Data from one research site for GCC19CART, ICT’s lead solid tumor program, for 3rd line plus relapsed/refractory metastatic colorectal cancer (R/R mCRC) shows patients receiving a dose of 2×10^6 CAR T cells / kg demonstrating a 57% (4/7) objective response rate.   Pre-Clinical Data demonstrates CoupledCAR® technology promotes efficient in vivo expansion and superior functionality…

Innovative Cellular Therapeutics (ICT) Receives FDA Fast Track Designation for GCC19CART, its Lead Solid Tumor Candidate, in the Treatment of Patients with Relapsed or Refractory Metastatic Colorectal Cancer 1000 667 Innovative Cellular Therapeutics

Innovative Cellular Therapeutics (ICT) Receives FDA Fast Track Designation for GCC19CART, its Lead Solid Tumor Candidate, in the Treatment of Patients with Relapsed or Refractory Metastatic Colorectal Cancer

GCC19CART is an autologous CAR T therapy candidate that has shown promising results in over 30 R/R mCRC patients in China  ICT plans to initiate a Phase 1 Trial of GCC19CART in the U.S. for the Treatment of R/R mCRC in mid-2022  ROCKVILLE, MARYLAND, April 19, 2022 (GLOBE NEWSWIRE) – Innovative Cellular Therapeutics, Inc. (ICT),…

Innovative Cellular Therapeutics Appoints Lucy Lu as Chief Operations Officer 1000 667 Innovative Cellular Therapeutics

Innovative Cellular Therapeutics Appoints Lucy Lu as Chief Operations Officer

Innovative Cellular Therapeutics (ICT), a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T cell therapies with a focus on solid tumors, today announced the appointment of Lucy Lu, M.D. as Chief Operations Officer.   “We are excited to welcome Lucy to the team during this critical time for the company,” said…

Innovative Cellular Therapeutics Appoints Robert Dallimore as SVP of Quality & Compliance 1000 1500 Innovative Cellular Therapeutics

Innovative Cellular Therapeutics Appoints Robert Dallimore as SVP of Quality & Compliance

Innovative Cellular Therapeutics (ICT), a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T cell therapies with a focus on solid tumors, today announced the appointment of Robert Dallimore as SVP of Quality & Compliance.   “I am very pleased to welcome Rob to ICT. This is a critical time for the…

ICT Receives FDA Clearance of IND Application to Initiate a Phase 1 Clinical Trial for GCC19CART 1366 911 Innovative Cellular Therapeutics

ICT Receives FDA Clearance of IND Application to Initiate a Phase 1 Clinical Trial for GCC19CART

ROCKVILLE, Md., Sept. 01, 2021 (GLOBE NEWSWIRE) — Innovative Cellular Therapeutics (ICT), a Maryland based clinical stage biotechnology company developing the CoupledCAR® platform of chimeric antigen receptor (CAR) T-cell therapies..

Innovative Cellular Therapeutics Appoints Eugene Kennedy as Chief Medical Officer 1366 907 Innovative Cellular Therapeutics

Innovative Cellular Therapeutics Appoints Eugene Kennedy as Chief Medical Officer

ROCKVILLE, Md., March 16, 2021 — Innovative Cellular Therapeutics (ICT), a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T cell therapies with a focus on solid tumors, today announced the appointment of Eugene (Gene) Kennedy, M.D. as Chief Medical Officer. Dr. Kennedy is an experienced biopharma executive with a track…

Innovative Cellular Therapeutics to Participate in Upcoming Investor Conferences 1704 1858 Innovative Cellular Therapeutics

Innovative Cellular Therapeutics to Participate in Upcoming Investor Conferences

ROCKVILLE, Md., Nov. 10, 2020 (GLOBE NEWSWIRE) — Innovative Cellular Therapeutics (ICT), a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T cell therapies for solid and liquid tumors, today announced its plans to participate in and host one-on-one meetings at three investor conferences this month. “We appreciate the opportunity to…

Innovative Cellular Therapeutics to Present CoupledCAR® Solid Tumor CAR-T Clinical Data at Upcoming Scientific Meetings 671 768 Innovative Cellular Therapeutics

Innovative Cellular Therapeutics to Present CoupledCAR® Solid Tumor CAR-T Clinical Data at Upcoming Scientific Meetings

ROCKVILLE, Md., Nov. 10, 2020 (GLOBE NEWSWIRE) — Innovative Cellular Therapeutics (ICT), a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T cell therapies for solid and liquid tumors, today announced its plans to present CoupledCAR® solid tumor CAR-T clinical data at two key oncology conferences. ICT will make data presentations…

  • 1
  • 2